Can Mindfulness-Based Cognitive Therapy Reduce Episodic Migraine Severity and Disability?
July 17th 2019Lead author Elizabeth K. Seng, PhD, shared insight into the findings of an exploration of the use of mindfulness-based cognitive therapy to reduce the impact of migraine on patients, as measured by Migraine Disability Assessment, as well as Headache Disability Inventory scores.
Manish Shah MD, MPH: How Telemedicine Can Reduce ED Use in Dementia
July 16th 2019The professor of emergency medicine at the University of Wisconsin-Madison School of Medicine and Public Health spoke about how telemedicine in senior living communities can effectively decrease ED use by individuals with dementia.
Future of Neurology Congress Will Offer Expert Insights on Hot Topics
July 15th 2019The International Congress on the Future of Neurology will take place this Fall in New York City, converging experts in neurology to discuss the latest data and best practices to better inform clinical decision-making.
Elzbieta Kuzma, PhD: Healthy Lifestyle Reduces Dementia Risk Despite Genetics
July 15th 2019The research fellow at the University of Exeter spoke about the findings from her observational study which showed that living a favorable lifestyle could offset the risk for dementia, even if that risk is genetically linked. 


Christopher Gottschalk, MD: Advantages of Eptinezumab and CGRP Inhibitors
July 14th 2019The director of headache medicine and chief of general neurology at Yale Medicine spoke about the significance of having CGRP inhibitors in migraine treatment, and how eptinezumab fits into the treatment landscape.
Dawn Buse, PhD: Where Are Patients With Migraine Seeking Care?
July 13th 2019The clinical professor of neurology at Albert Einstein College of Medicine spoke about the trends revealed by the OVERCOME study, and how this data can be used to improve the management of the millions of patients with migraine in the US.
Richard Lipton, MD: Eptinezumab Maintains Reductions in the Impact of Migraine
July 13th 2019The director of the Montefiore Headache Center and professor of neurology at Albert Einstein College of Medicine spoke about the results of an analysis of eptinezumab’s effect on the severity of migraine and its impact on patients’ lives.
Real-World Erenumab Data Shows High Use in Chronic Migraine and Persistence to Therapy
July 13th 2019Real-world data of erenumab indicates that a large number of patients are the chronic migraine population, and there is a high rate of persistence to the anti-CGRP therapy. The most commonly prescribed dose of erenumab was 70 mg.
Low-Dose DFN-11 Successful in Relieving Severe and Moderate Acute Migraine Pain
July 13th 2019Patients with migraine who reported both moderate and severe pain intensity during headache attacks experienced high rates of relief and freedom from pain and their most bothersome symptom when treated with 3-mg sumatriptan injection, DFN-11.
HIT-6 Questionnaire Relevant and Useful in Migraine Assessments
July 12th 2019Despite ongoing discussion regarding the 6-item Headache Impact Test’s relevance in the migraine population—for which it was not specifically developed—the test has been shown to be a useful tool in the assessment of patients with migraine.
Opioid Use Remains High in Acute Migraine Settings
July 11th 2019Survey data revealed 36% of patients with migraine with prescription medications were using opioids in acute management, though data also reinforced that receiving a diagnosis of migraine or chronic migraine was associated with a significantly decreased likelihood of opioid use.